Immune Related Adverse Events Associated with Checkpoint Inhibition in the Setting of CAR T-Cell Therapy: A Case Series

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy leads to high overall response rates of ∼80% even in heavily pre-treated diffuse large B-cell lymphoma (DLBCL), though relapse-free survival drops to ∼40% within the first 12 months. There are early data suggesting that inhibiting the programmed cell death protein 1: programmed cell death ligand 1 (PD-1: PD-L1) checkpoint axis may dec rease T cell exhaustion and improve CAR T-cell function. However, there is limited data regarding the toxicity of sequencing these two modalities.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2019 Category: Hematology Authors: Swetha Kambhampati, Lissa Gray, Bita Fakhri, Mimi Lo, Khoan Vu, Shagun Arora, Lawry Kaplan, Weiyun Z. Ai, Charalambos Andreadis Tags: Case Report Source Type: research